Explore our news page for thought leadership articles, technical expertise and the latest developments in the world of innovation funding.
The Grants team at Myriad Associates are proud to announce that they have secured over €30m from the Disruptive Technologies Innovation Fund (DTIF) for five, round 3 health and life science projects.
Myriad Associates managed to grow by 20% and break the £2million turnover barrier during a turbulent year. Our CEO reveals the secret behind Myriad Associates success.
After an incredibly tough year filled with uncertainty and worry, Myriad Associates are pleased to welcome three new additions to the team!
Onkimmune was founded in 2015 with the goal of developing novel anti-cancer therapies using Natural Killer (NK) cells.
Thank you for subscribing to our newsletter.
Back to form